
Nivolumab (Opdivo) Approved in Japan for the Treatment of Advanced Melanoma
Nivolumab, the first PD-1 inhibitor, was approved in Japan for treating unresectable melanoma. It has been developed in Japan by Ono Pharmaceutical, which also has rights in Korea and Taiwan.
The first immunotherapy product to act on the programmed death (PD) pathway has just been granted its first approval in the world.
Nivolumab has been
This is one of the most highly anticipated drug approvals in oncology — the product has shown
The Japanese approval for nivolumab is for use in unresectable melanoma.
Source: Medscape
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.